PDE Inhibitors - Pipeline Insight, 2024

This “PDE Inhibitors - Pipeline Insight, 2024” report provides comprehensive insights about 40+ companies and 40+ pipeline drugs in PDE Inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

PDE Inhibitors Understanding

PDE Inhibitors: Overview

Phosphodiesterase inhibitors (PDE inhibitors) are a class of agents acting on specific phosphodiesterase enzymes in target cells and are FDA approved for the management of chronic obstructive pulmonary disease, erectile dysfunction, pulmonary arterial hypertension, psoriasis, psoriatic arthritis, and atopic dermatitis. Phosphodiesterase enzymes' essential role serves to separate the phosphate group from the target cell and decrease cyclic adenosine monophosphate (c AMP) or cyclic guanosine monophosphate (c GMP). The inhibition of these enzymes further prevents the degradation of cAMP or cGMP, exhibiting smooth muscle relaxation, vasodilatory, and bronchodilatory effects. Hypersensitivity is an absolute contraindication to all phosphodiesterase inhibitors. Nitrites are contraindicated to use alongside PDE-5 inhibitors: sildenafil, tadalafil, vardenafil, and avanafil, as they may result in severe hypotension. Relative contraindication such as pre-existing cardiovascular disease, resting hypotension, and anti-hypertensive use require evaluation before phosphodiesteraseinhibitoruse.

PDE Inhibitors - Pipeline Insight, 2024 report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the PDE Inhibitors pipeline landscape is provided which includes the disease overview and PDE Inhibitors treatment guidelines. The assessment part of the report embraces, in depth PDE Inhibitors commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, PDE Inhibitors collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence PDE Inhibitors R&D. The therapies under development are focused on novel approaches to treat/improve PDE Inhibitors.

PDE Inhibitors Emerging Drugs Chapters

This segment of the PDE Inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

PDE Inhibitors Emerging Drugs

ARQ-151: Arcutis Biotherapeutics Topical roflumilast cream (ARQ-151) is a small molecule inhibitor of phosphodiesterase type 4 (PDE4), an intracellular enzyme that increases the production of proinflammatory mediators and decreases production of anti-inflammatory mediators, and has been implicated in a wide range of inflammatory diseases including psoriasis, eczema, and chronic obstructive pulmonary disease (COPD). Topical roflumilast cream is a highly potent, selective PDE4 inhibitor in a convenient, once-daily formulation that Arcutis is developing for chronic plaque psoriasis and atopic dermatitis. Roflumilast is 25-300X more potent than the two other FDA-approved PDE4 inhibitors used in dermatology and has a well-established safety profile with more than 1 million patient years of exposure in clinicaluse.

Ensifentrine: Verona Pharma Ensifentrine is a first-in-class, inhaled, dual inhibitor of the phosphodiesterase 3 (PDE3) and phosphodiesterase 4 (PDE4) enzymes. This dual inhibition enables it to combine bronchodilator and anti-inflammatory properties in one compound, differentiating it from existing drug classes used to treat COPD, including corticosteroids, beta2-agonists and anti-muscarinics. It is currently in Phase III stage of development for Chronic obstructive pulmonary disease and is being developed VeronaPharma.

PDE Inhibitors: Therapeutic Assessment

This segment of the report provides insights about the different PDE Inhibitors drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in PDE Inhibitors

There are approx. 40+ key companies which are developing the therapies for PDE Inhibitors. The companies which have their PDE Inhibitors drug candidates in the most advanced stage, i.e. Pre-registration include, Arcutis Biotherapeutics.

Phases

This report covers around 40+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

PDE Inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical.

Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

PDE Inhibitors: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses PDE Inhibitors therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging PDE Inhibitors drugs.

PDE Inhibitors Report Insights

• PDE Inhibitors Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

PDE Inhibitors Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing PDE Inhibitors drugs?
• How many PDE Inhibitors drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of PDE Inhibitors?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the PDE Inhibitors therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for PDE Inhibitors and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Arcutis Biotherapeutics
• Chiesi Farmaceutici
• Imara Inc
• Verona Pharma
• Eisai Inc
• vTv Therapeutics
• Tetra Therapeutics
• Palobiofarma

Key Products

• ARQ-151
• CHF-6001
• IMR-687
• Ensifentrine
• E 2027
• HPP-737
• BPN-14770
• BTX-2640
• PBF-999

This product will be delivered within 2-4 business days.